FDA approves Topamax for migraine prevention in adolescents

On March 28, the U.S. Food and Drug Administration approved Topamax (topiramate) for prevention of migraine headaches in adolescents ages 12 to 17. This is the first FDA approval of a drug for migraine prevention in this age group. Read more.

LEAVE A REPLY

Please enter your comment!
Please enter your name here